On OX40 and PD-1 combination: Why should OX40 be first in sequence?

Mario P. Colombo

doi:10.1158/1078-0432.CCR-17-2332

On OX40 and PD-1 combination: Why should OX40 be first in sequence?

Mario P. Colombo

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Review article › peer-review

Abstract

The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence.

Original language	English
Pages (from-to)	5999-6001
Number of pages	3
Journal	Clinical Cancer Research
Volume	23
Issue number	20
DOIs	https://doi.org/10.1158/1078-0432.CCR-17-2332
Publication status	Published - Oct 15 2017

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-17-2332

Fingerprint Dive into the research topics of 'On OX40 and PD-1 combination: Why should OX40 be first in sequence?'. Together they form a unique fingerprint.

Cite this

@article{f1192c1dcd2b41829555d09412947573,

title = "On OX40 and PD-1 combination: Why should OX40 be first in sequence?",

abstract = "The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence.",

author = "Colombo, {Mario P.}",

year = "2017",

month = oct,

day = "15",

doi = "10.1158/1078-0432.CCR-17-2332",

language = "English",

volume = "23",

pages = "5999--6001",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "20",

}

TY - JOUR

T1 - On OX40 and PD-1 combination

T2 - Why should OX40 be first in sequence?

AU - Colombo, Mario P.

PY - 2017/10/15

Y1 - 2017/10/15

N2 - The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence.

AB - The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence.

UR - http://www.scopus.com/inward/record.url?scp=85031497561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031497561&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-17-2332

DO - 10.1158/1078-0432.CCR-17-2332

M3 - Review article

AN - SCOPUS:85031497561

VL - 23

SP - 5999

EP - 6001

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -